Syncona Shs GBP (GB:SYNC)

LSE:SYNC

SYNC

Syncona Shs GBP

RESEARCH TOOLSreports

Want to see GB:SYNC full AI Analyst Report?

Syncona Shs GBP (SYNC) Price & Analysis

Q: What was Syncona Shs GBP ’s price range in the past 12 months?

Syncona Shs GBP lowest share price was 86.80 p and its highest was 102.60 p in the past 12 months.

Q: What is Syncona Shs GBP ’s market cap?

Syncona Shs GBP ’s market cap is £585.08M.

Q: When is Syncona Shs GBP ’s upcoming earnings report date?

Syncona Shs GBP ’s upcoming earnings report date is Nov 12, 2026 which is in 142 days.

Q: How were Syncona Shs GBP ’s earnings last quarter?

Syncona Shs GBP released its earnings results on Jun 18, 2026. The company reported 0.027 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.027 p.

Q: Is Syncona Shs GBP overvalued?

According to Wall Street analysts Syncona Shs GBP ’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Syncona Shs GBP pay dividends?

Syncona Shs GBP pays a Annually dividend of 2.3 p which represents an annual dividend yield of N/A. See more information on Syncona Shs GBP dividends here

Q: What is Syncona Shs GBP ’s EPS estimate?

Syncona Shs GBP ’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Syncona Shs GBP have?

Syncona Shs GBP has 608,193,050 shares outstanding.

Q: What happened to Syncona Shs GBP ’s price movement after its last earnings report?

Syncona Shs GBP reported an EPS of 0.027 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.99%.

Q: Which hedge fund is a major shareholder of Syncona Shs GBP ?

Currently, no hedge funds are holding shares in GB:SYNC

19 Followers

SYNC Stock Chart & Stats

93.90 p

1.15 p(1.28%)

At close: Jan 09 4:00 PM EST

93.90 p

1.15 p(1.28%)

Day’s Range― - ―

52-Week Range86.80 p - 102.60 p

Previous CloseN/A

Volume94.05K

Average Volume (3M)483.92K

Market Cap

£585.08M

Enterprise Value589.73M

Total Cash (Recent Filing)£213.00K

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding608,193,050

10 Day Avg. Volume510,558

30 Day Avg. Volume483,919

Financial Highlights & Ratios

PEG Ratio0.65

Price to Book (P/B)0.52

Price to Sales (P/S)9.39

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)<0.01

Revenue Forecast (FY)£49.14M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthZero reported total debt and a large equity base materially lower financial risk and provide durable capital to support long clinical timelines and follow-on funding. This conservative position preserves optionality and resilience during multi-year biotech development cycles.

Focused Investment ModelA concentrated life-sciences investment model that founders and scales companies aligns incentives for value creation across clinical milestones. Owning early-stage stakes and supporting portfolio firms offers structural upside when therapies advance or exits occur, sustaining long-term return potential.

Operating Cash Flow HistoryConsistent positive operating cash flow in recent years shows the business can generate cash from its operations and investment activities intermittently, helping fund follow-on investments and support portfolio firms without relying solely on external capital in normal cycles.

Bears Say

Inconsistent ProfitabilityShifting to consecutive loss years weakens the firm's ability to demonstrate repeatable return generation on its invested capital. Persistent negative earnings reduce retained earnings growth and constrain the pace at which the company can internally fund new investments long-term.

Weak Free Cash Flow ConversionA collapse to zero free cash flow signals deteriorating cash conversion or higher cash needs for portfolio support. Over multi-quarter horizons this can force reliance on external funding, diluting optionality and increasing vulnerability during periods when capital markets are tighter.

Volatile Revenue TrendsLarge swings in revenue reduce visibility into sustainable earnings power and complicate planning for R&D and follow-on investments. For an investment vehicle tied to portfolio valuations, volatile reported revenue highlights sensitivity to timing of realizations and makes cash planning less predictable.

Syncona Shs GBP News

Syncona Director Increases Stake with Share Purchase on London Stock Exchange

Syncona Shs GBP ( ($GB:SYNC) ) has shared an announcement. Syncona Limited reported that non-executive director John Patrick...

2d ago

Syncona Sets £250m Return Target as Portfolio Advances to Late-Stage Trials

Syncona Shs GBP ( ($GB:SYNC) ) has issued an update. Syncona reported largely stable full-year results, with net...

5d ago

Syncona appoints veteran investment specialist Norman Crighton to board

Syncona Shs GBP ( ($GB:SYNC) ) has issued an update. Syncona Ltd has appointed veteran investment company specialist...

7d ago

Syncona Wins Shareholder Backing for New Investment Policy and Board Refresh

An update from Syncona Shs GBP ( ($GB:SYNC) ) is now available. Syncona shareholders have overwhelmingly approved a...

4M ago

Syncona’s Quell Therapeutics Advances Lead CAR-Treg Autoimmune Therapy and Refocuses Pipeline

The latest update is out from Syncona Shs GBP ( ($GB:SYNC) ). Syncona portfolio company Quell Therapeutics has...

4M ago

Syncona Refines Investment Strategy and Incentives Ahead of Shareholder Vote

Syncona Shs GBP ( ($GB:SYNC) ) has issued an announcement. Syncona Limited has published a circular detailing a...

4M ago

Syncona Posts Strong Q3 NAV Gains as Beacon Financing and Late‑Stage Pipeline Drive Outlook

The latest update is out from Syncona Shs GBP ( ($GB:SYNC) ). Syncona reported a solid third quarter,...

5M ago

Syncona Ups Beacon Therapeutics Stake as Gene Therapy Group Raises $75m Series C

Syncona Shs GBP ( ($GB:SYNC) ) has shared an update. Syncona has committed $24.5 million to Beacon Therapeutics’...

6M ago

Syncona Limited Announces Total Voting Rights Update

Syncona Shs GBP ( ($GB:SYNC) ) just unveiled an announcement. Syncona Limited has announced that as of 28...

7M ago

Syncona Limited to Issue New Shares Under Incentive Scheme

Syncona Shs GBP ( ($GB:SYNC) ) has issued an announcement. Syncona Limited announced the issuance of 334,788 new...

7M ago

SYNC FAQ

What was Syncona Shs GBP ’s price range in the past 12 months?

Syncona Shs GBP lowest share price was 86.80 p and its highest was 102.60 p in the past 12 months.

What is Syncona Shs GBP ’s market cap?

Syncona Shs GBP ’s market cap is £585.08M.

When is Syncona Shs GBP ’s upcoming earnings report date?

Syncona Shs GBP ’s upcoming earnings report date is Nov 12, 2026 which is in 142 days.

How were Syncona Shs GBP ’s earnings last quarter?

Syncona Shs GBP released its earnings results on Jun 18, 2026. The company reported 0.027 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.027 p.

Is Syncona Shs GBP overvalued?

According to Wall Street analysts Syncona Shs GBP ’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Syncona Shs GBP pay dividends?

Syncona Shs GBP pays a Annually dividend of 2.3 p which represents an annual dividend yield of N/A. See more information on Syncona Shs GBP dividends here

What is Syncona Shs GBP ’s EPS estimate?

Syncona Shs GBP ’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Syncona Shs GBP have?

Syncona Shs GBP has 608,193,050 shares outstanding.

What happened to Syncona Shs GBP ’s price movement after its last earnings report?

Syncona Shs GBP reported an EPS of 0.027 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.99%.

Which hedge fund is a major shareholder of Syncona Shs GBP ?

Currently, no hedge funds are holding shares in GB:SYNC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Syncona Shs GBP Stock Smart Score

Neutral

Fundamentals

Return on Equity

-9.02%

Trailing 12-Months

Asset Growth

-10.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Syncona Shs GBP

Syncona Limited operates as an investment fund, strategically deploying capital across a broad spectrum of investment vehicles, including hedge funds, equity funds, and long-duration alternative investments, spanning numerous asset classes. The firm actively oversees portfolios dedicated to private equity, debt instruments, fixed income securities, and various other alternative strategies. A significant portion of its focus is directed towards the healthcare and life sciences sectors, with particular interest in advancements such as cell therapy, gene therapy, biologics, and small molecules. Syncona's global reach extends to both public equity and fixed-income markets. Its core objective is to generate compelling medium to long-term returns by identifying and investing in leading long-only and alternative investment funds led by experienced managers, typically through separately managed account portfolios, to execute these multi-asset class strategies.